Clinical Trials
29 trialsNOCON
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Electroacupuncture for Opioid-Induced Constipation in Cancer Patients: A Randomized Clinical Trial
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study
International University of Health and Welfare
OIC1
BioGaia Pharma AB
E-StOIC
University of Dublin, Trinity College
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Henan Cancer Hospital
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
BioDelivery Sciences International
OMAMA
Amsterdam UMC, location VUmc
NACASY
Kyowa Kirin Co., Ltd.
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Fondazione ANT Italia ONLUS
OIC
Takeda
StOIC-2
Royal Surrey County Hospital NHS Foundation Trust
StOIC-1
Royal Surrey County Hospital NHS Foundation Trust
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
Bausch Health Americas, Inc.
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Forest Laboratories
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Naloxone SR Capsules in Patients With Opioid Induced Constipation
S.L.A. Pharma AG
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
Novartis
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis